B O O K - American College of Rheumatology

More documents

Recommendations

Info

ACR/ARHP Poster Session B 1098. Biomarkers Predictors of Good EULAR Response to B Cell Depletion Therapy (BCDT) in Seropositive Rheumatoid Arthritis Patients. Gianfranco Ferraccioli 3 , Barbara Tolusso 3 , Francesca Bobbio Pallavicini 4 , Elisa Gremese 3 , Viviana Ravagnani 1 , Maurizio Benucci 5 , Edoardo Podesta’ 2 , Fabiola Atzeni 6 , Giusy Peluso 3 , G. Biasi 1 , Mariangela Manfredi 5 , Piercarlo Sarzi Puttini 6 , Bruno Lagana’ 2 and Carlomaurizio Montecucco 4 , 1 Department of Clinical and Experimental Medicine, Section of Rheumatology & Internal Medicine, University of Verona, Verona, Italy, 2 Division of Clinical Immunology and Rheumatology, S. Andrea University Hospital, “Sapienza” University of Rome, II School of Medicine, Rome, Italy, 3 Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 4 Division of Rheumatology, University of Pavia, IRCCS S. Matteo Foundation, Pavia, Italy, 5 Rheumatology Unit, Department of Internal Medicine, Ospedale di S. Giovanni di Dio, Florence, Italy, 6 Rheumatology Unit, University Hospital L. Sacco, Milan, Italy. 1099. Candidate Gene Analysis in US Veteran Rheumatoid Arthritis Patients with Clinical Improvement during Treatment with Anti-Tumor Necrosis Factor Agents in the Veterans Affairs Rheumatoid Arthritis (VARA) Registry. Grant W. Cannon 5 , Roger K. Wolff 5 , Jian Ying 8 , Candace L. Hayden 6 , Brian C. Sauer 6 , Jeffrey R. Curtis 7 , Dannette S. Johnson 3 , Gail S. Kerr 9 , J. Steuart Richards 10 , Liron Caplan 2 , Andreas Reimold 1 and Ted R. Mikuls 4 , 1 Dallas VA and University of Texas Southwestern, 2 Denver VA and University of Colorado, 3 Jackson VA and University of Mississippi, 4 Omaha VA and University of Nebraska, 5 Salt Lake City VA and University of Utah, Salt Lake City, UT, 6 Salt Lake City VA and University of Utah, 7 University of Alabama, 8 University of Utah, 9 Washington DC VA and Georgetown and Howard Universities, 10 Washington DC VA and Georgetown University. 1100. CCR1 Antagonist CCX354-C in Phase 2 Clinical Development for Rheumatoid Arthritis. Daniel J. Dairaghi, Vittorio Marchesin, Daniel A. Johnson, Shichang Miao, Lisa C. Seitz, Yu Wang, Penglie Zhang, Jay P. Powers, Bert Ho, Pirow J. Bekker, Juan C. Jaen and Thomas J. Schall, ChemoCentryx. 1101. Change in CRP at 12 Weeks Predicts the Risk of Rapid Radiographic Progression at 2 Years in Methotrexate-Treated Patients with Early Rheumatoid Arthritis. Boulos Haraoui 4 , Paul Emery 3 , Neelufar Mozaffarian 1 , Benoit Guerette 2 , Hartmut Kupper 2 , Kaushik Patra 2 and Ed C. Keystone 5 , 1 Abbott Laboratories, Abbott Park, IL, 2 Abbott Laboratories, 3 Chapel Allerton Hospital, Leeds, United Kingdom, 4 Institut de Rhumatologie, Montreal, QC, Canada, 5 University of Toronto, Toronto, ON, Canada. 1102. Clinical and Radiographic Implications of Time to Treatment Response in Patients with Early Rheumatoid Arthritis. Ed C. Keystone 7 , Michael E. Weinblatt 4 , Boulos Haraoui 5 , Benoit Guerette 2 , Neelufar Mozaffarian 1 , Kaushik Patra 3 and Arthur Kavanaugh 6 , 1 Abbott Laboratories, Abbott Park, IL, 2 Abbott Laboratories, France, 3 Abbott Laboratories, 4 Brigham &Womens Hospital, Boston, MA, 5 Institut de Rhumatologie, Montreal, QC, Canada, 6 University of California-San Diego, La Jolla, CA, 7 University of Toronto, Toronto, ON, Canada. 1103. Composite Remission Using Clinical, Structural, and Functional Criteria in Patients with Rheumatoid Arthritis (RA) Treated with Etanercept. Mark C. Genovese 4 , Andrew S. Koenig 3 , Grace S. Park 1 and Scott W. Baumgartner 2 , 1 Amgen Inc., Thousand Oaks, CA, 2 Amgen, Inc., Thousand Oaks, CA, 3 Pfizer Inc., Blue Bell, PA, 4 Stanford University, Sunnyvale, CA. 1104. DAS-Driven Therapy Versus Routine Care in Patients with Recent-Onset Active Rheumatoid Arthritis: Data from the GUEPAR Trial and ESPOIR Cohort. Martin Soubrier 1 , Cédric Lukas 2 , Jean Sibilia 3 , Bruno Fautrel 5 , Laure Gossec 4 , Simon Patternotte 4 and Maxime Dougados 4 , 1 CHU Clermont-Ferrand, Sevice de Rhumatologie, F-63003, Clermont-Ferrand, Puy-dedôme, France, 2 CHU Montpellier, Service de Rhumatologie, F-34295 Montpellier, France, 3 CHU Strasbourg, Service de Rhumatologie, Strasbourg, France, 4 Hôpital Cochin, Service de Rhumatologie, F-75014, Paris, France, 5 Hôpital Pitié-Salpétrière, Service de Rhumatologie, F-75013, Paris, France. 1105. Differential Serum Glycosylation Changes in Rheumatoid and Psoriatic Arthritis – In Response to Anti-TNF Therapy. Azita Alavi 1 , Oliver M. FitzGerald 3 , Emily S. Collins 4 , Owen Fraser 2 , Edward Tarelli 1 , Chin Teck Ng 4 , Barry Bresnihan 5 , Douglas J. Veale 4 and John S. Axford 1 , 1 St. Georges University of London, London, United Kingdom, 2 St. Georges University of London, London, United Kingdom, 3 St. Vincent’s University Hospital, Dublin, Ranelagh Dublin, Ireland, 4 St. Vincent’s University Hospital, Dublin, Dublin, Ireland, 5 St. Vincent’s University Hospital, Dublin, Co. Dublin, Ireland. 1106. Double-Blind, Randomized, Controlled, Placebo-Included, Pilot Study Comparing Classical Ayurvedic Medicine, Methotrexate, and Their Combination in RA. Daniel E. Furst 3 , Manorama M. Venkatraman 4 , Mary McGann 1 , P. Ram Manohar 1 , Cathryn Booth-LaForce 4 , Dinesh Khanna 2 , K. G. Raveendran 1 , Reshmi Sarin 1 , Anita Mahapatra 1 , Jidesh Gopinath 1 and P. R. Krishna Kumar 1 , 1 The Ayurvedic Trust, 2 UCLA, 3 University of California Los Angeles Medical School, Los Angeles, CA, 4 University of Washington. 1107. HM-A42, a Novel Inhibitor of IKKβ Kinase Reverses Clinical and Histological Disease Parameters in Multiple Autoimmune Disease Models. Yu Cai 1 , Xinrong Wang 1 , Ping Ren 1 , Changwu Lu 1 , Jianlin He 1 , Xiaoming Dai 3 , Qianqian Dong 1 , Jun Yu 3 , Lei Fang 2 , Xiaoning Yang 1 , Lei Jiang 3 , Jia Li 1 , Weifang Xue 1 , Pingmin Tang 1 , Jian Wang 1 , Fang Yin 3 , Yongjuan Yu 3 , Jingshui Li 3 , Yang Sai 3 , James Yan 3 , Jianguo Ji 3 , Weiguo Qing 3 , Weiguo Su 3 and Haoran Zhao 1 , 1 Hutchison MediPharma Ltd, Shanghai, China, 2 Hutchison MediPharma Ltd, Shanghai, China, 3 Hutchison MediPharma Ltd. 1108. Impact of Genetic Interactions on Response to Adalimumab Plus Methotrexate Versus Methotrexate Alone: Six Month Results of the OPTIMA Trial. Alla Skapenko 3 , Kaushik Patra 2 , Hartmut Kupper 1 and Hendrik Schulze-Koops 3 , 1 Abbott GmbH & Co. KG, Ludwigshafen, Germany, 2 Abbott Laboratories, Abbott Park, IL, 3 University of Munich, Munich, Germany. 1109. Improved Disease Control in Response to Tocilizumab Therapy Is Accompanied by Decreased Platelet Reactivity in Patients with Rheumatoid Arthritis. Paul A. MacMullan 3 , Anne M. Madigan 1 , Paola Bagaglia 2 , Dermot Kenny 3 and Geraldine M. McCarthy 1 , 1 Mater Misericordiae Univ. Hosp, Dublin, Ireland, 2 Mater Misericordiae Univ. Hosp, Dublin, Ireland, 3 RCSI, Dublin, Ireland. 1110. In Patients with Early Inflammatory Polyarthritis, ACPA Positivity and Inefficacy of the First DMARD Are Associated with the Need To Start a Biologic Later on: Results from the Norfolk Arthritis Register (NOAR). S. M. M. Verstappen 1 , M. Lunt 1 , D. K. Bunn 2 , D. G. I. Scott 2 and D. P. M. Symmons 1 , 1 Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2 Norfolk Arthritis Register, Norfolk and Norwich University Hospital, Norwich, United Kingdom, United Kingdom. 216 2010 Program Book
ACR/ARHP Poster Session B 1111. Increasing Chance of Remission in Patients with Rheumatiod Arthritis. Anja Strangfeld 1 , Maria Eveslage 3 , Martin Aringer 4 , Rainer Dockhorn 5 , Matthias Schneider 6 , Joachim Listing 3 and Angela Zink 2 , 1 German Rheumatism Research Center, Berlin, Germany, 2 German Rheumatism Research Center and Charité University Medicine Berlin, 3 German Rheumatism Research Center, Berlin, 4 Rheumatologist, Dresden, Germany, 5 Rheumatologist, Weener, Weener, Germany, 6 Scientific Advisory Board, Düsseldorf. 1112. Influence of ESR on EULAR Response Rates in Patients Treated with Tocilizumab. Results from the German Biologics Register RABBIT. Anja Strangfeld 1 , Maria Eveslage 1 , Joachim Listing 1 , Peter Herzer 5 , Anke Liebhaber 4 , Brigitte Krummel-Lorenz 3 and Angela Zink 2 , 1 German Rheumatism Research Center, Berlin, Germany, 2 German Rheumatism Research Center and Charité Berlin, Berlin, Germany, 3 Rheumatologist Frankfurt/M, Frankfurt, Germany, 4 Rheumatologist Halle/S, Halle/Saale, Germany, 5 Scientific Advisory Board, Munich, Munich, Germany. 1113. Joint Space Narrowing Has a Stronger Impact on Physical Function Than Joint Erosion: Results from 8-Year Longitudinal Analyses. Desiree M. Van Der Heijde 2 , Robert Landewe 3 , Benoit Guerette 1 , Sanjoy Roy 1 , Kaushik Patra 1 and Ed C. Keystone 4 , 1 Abbott Laboratories, 2 Leiden University Medical Center, Meerssen, The Netherlands, 3 Univ Hosp Maastricht, Maastricht, The Netherlands, 4 University of Toronto, Toronto, ON, Canada. 1114. Magnetic Resonance Imaging Assessments of Patients with RA and Their Association with Clinical and Radiographic Outcomes. Paul Emery 3 , Desiree M. Van Der Heijde 6 , Mikkel Østergaard 5 , Philip G. Conaghan 4 , Mark C. Genovese 7 , Ed C. Keystone 9 , Roy M. Fleischmann 8 , Weichun Xu 1 , Stephen Xu 1 , Elizabeth C. Hsia 2 and Mahboob U. Rahman 2 , 1 Centocor Research and Development, Inc., 2 Centocor Research and Development, Inc./Univ. of Pennsylvania School of Medicine, Malvern, PA, 3 Chapel Allerton Hospital, Leeds, United Kingdom, 4 Chapel Allerton Hospital, Leeds, United Kingdom, 5 Copenhagen University Hospital at Glostrup and Hvidovre, 6 Leiden University Medical Center, Meerssen, The Netherlands, 7 Stanford University, Sunnyvale, CA, 8 University of Texas SW Medical Center, Dallas, TX, 9 University of Toronto, Toronto, ON, Canada. 1115. Optimal Dose Prediction by Pharmacokinetic and Biomarker Response of Subcutaneous Tocilizumab Treatment – A Phase I/II Study Evaluating the Safety, Pharmacokinetics and Clinical Response in Patients with Rheumatoid Arthritis. Shuji Ohta 8 , Tomomi Tsuru 5 , Kimio Terao 2 , Seiji Mogi 7 , Midori Suzaki 4 , Hitoshi Nakashima 3 , Eisuke Shono 6 , Eriko Tarumi 1 and Masato Imai 6 , 1 Chugai Clinical Research Center Co., Ltd, 2 Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, 3 Fukuoka University, 4 Med Co LTA PS Clinic, 5 Med Co LTA PS Clinic, Fukuoka, Japan, 6 Shono Rheumatism Clinic, 7 Taga General Hospital, Hitachi, Ltd, Japan 8 Taga General Hospital, Hitachi, Ltd, Japan. 1116. Preclinical Development of Autologous, Autoantigen-Loaded Dendritic Cells Modified with Bay11-7082 for Tolerizing Immunotherapy in Anti-Citrullinated Peptide Antibody Positive Rheumatoid Arthritis Patients Bearing the HLA-DR Shared Epitope. Sakoontalla Ramnoruth 2 , Marion Brunck 2 , Claire Hyde 2 , Shayna Street 2 , Geoffrey Strutton 1 , Christelle Capini 2 , Sebastien Bertin-Maghit 2 , Brendan O’Sullivan 2 and Ranjeny Thomas 2 , 1 Queensland Health Pathology, 2 University of Queensland Diamantina Institute. 1117. Prediction of One-Year Response to Etanercept and Methotrexate in Rheumatoid Arthritis Patients in TEMPO. Jeffrey R. Curtis 4 , Shuo Yang 7 , Lang Chen 6 , Grace S. Park 1 , Bojena Bitman 2 , Brian C. Wang 3 , Iris Navarro-Millan 5 and Arthur Kavanaugh 8 , 1 Amgen Inc., Thousand Oaks, CA, 2 Amgen Inc., South San Francisco, CA, 3 KForce Clinical Research, South San Francisco, CA, 4 University of Alabama - Brimingham, Birmingham, AL, 5 University of Alabama at Birmingham, Vestavia, AL, 6 University of Alabama at Birmingham, Birmingham, AL, 7 University of Alabama at Birmingham, 8 University of California-San Diego, La Jolla, CA. 1118. Predictors of Response to Rituximab in Patients with Active Rheumatoid Arthritis and Inadequate Response to Anti-TNF Agents or Traditional DMARD. Javier Narvaez 4 , Cesar Díaz Torné 2 , Jose Miguel Ruiz 3 , Maria Victoria Hernández 1 , Vicens Torrente 2 , Sergio Ros 3 , Cesar Díaz López 2 , Arturo Rodriguez de la Serna 2 , Raimon Sanmartí 1 and Joan Miquel Nolla 4 , 1 Department of Rheumatology, Hospital Clinic, Barcelona, Spain, 2 Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 3 Department of Rheumatology, Hospital de Viladecans, Barcelona, Spain, 4 Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain. 1119. Proof of Concept Study for a Potent p38 MAPK Dual Action Inhibitor BMS-582949 in Subjects with RA Receiving Concomitant Methotrexate. Mark C. Genovese 6 , Ling Gao 3 , Jie Yin 3 , Stefani Smith 3 , Michael E. Weinblatt 1 , Josef S. Smolen 5 , Xiaoning Wang 3 , Gary Schieven 3 , Juan A. Garcia-Meijide 4 , Robert Latek 3 , Richard Pasternak 3 , Sanjeev Kaul 3 , Amit Roy 3 , Ralph Raymond 3 , Ulrich Thienel 3 and Jingsong Wang 2 , 1 Brigham & Womens Hospital, Boston, MA, 2 Bristol-Myers Squibb, Wayne, PA, 3 Bristol-Myers Squibb, 4 Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, 5 Krankenhaus Lainz, Vienna, Austria, 6 Stanford University, Sunnyvale, CA. 1120. Radiographic Progression Correlates Well with Patient- Reported RAPID3 Disease Activity Levels in Methotrexate (MTX)-Naive Patients with Early Rheumatoid Arthritis (RA): Insights from the AGREE Study. Edward C. Keystone 3 , Rene Westhovens 4 , Diane Moniz Reed 1 , Allison Covucci 1 and Alvin F. Wells 2 , 1 Bristol-Myers Squibb, Princeton, NJ, 2 Rheum & Immunotherapy Center, Oak Creek, WI, 3 University of Toronto, Toronto, ON, Canada, 4 UZ Gasthuisburg, Leuven, Leuven, Belgium. 1121. REGN88/SAR153191, a Fully-Human Interleukin-6 Receptor Monoclonal Antibody, Reduces Acute Phase Reactants in Patients with Rheumatoid Arthritis: Preliminary Observations from Phase 1 Studies. Allen R. Radin 1 , Scott J. Mellis 1 , Martine Jasson 3 , Douglas Nadler 2 , Pavel Belomestnov 2 , Richard Wu 2 , Stephanie Biedermann 2 , Damir Skific 2 and Jennifer Hamilton 2 , 1 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 2 Regeneron Pharmaceuticals, Inc., 3 Sanofi-aventis, SA. 1122. Results from a Phase I Study of MLTA3698A, a Novel Anti- Lymphotoxin-a Monoclonal Antibody: Safety, Tolerability and Biologic Activity in Patients with Active Rheumatoid Arthritis. Brinda Emu 2 , Diana Luca 3 , Carolyn Offutt 3 , Jane Grogan 3 , John Davis 3 , Bernadette Rojkovich 1 , Marna Williams 3 , Meina Tang 3 and June Lee 3 , 1 Budai Irgalmasrendi, 2 Genentech, Inc., South San Francisco, CA, 3 Genentech, Inc.. 2010 Program Book 217
Page 1 and 2:
program B O O K Pre-Conference Cour
Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
Page 11 and 12:
the written consent of the ACR is p
Page 13 and 14:
Shuttle Bus Service See shuttle sig
Page 15 and 16:
ACR Resource Center Hours: Sunday,
Page 17 and 18:
ACR Hotels + Map Complimentary shut
Page 19 and 20:
to the premier meeting in rheumatol
Page 21 and 22:
ACR Clinical Research Conference c/
Page 23 and 24:
4:20 PM Germinal Center Reactions A
Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
Page 27 and 28:
Upon completion of this session, pa
Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
Page 31 and 32:
B301 Dermatological Manifestations
Page 33 and 34:
Session Overview: The innate immune
Page 35 and 36:
Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
Page 39 and 40:
and insufficiency • recall source
Page 41 and 42:
Session Overview: The advent of bio
Page 43 and 44:
2:45 pm 641. Major Improvements in
Page 45 and 46:
5 University of Twente and Medisch
Page 47 and 48:
ACR/ARHP Combined Abstract Session
Page 49 and 50:
REF 25th Anniversary Celebration 2:
Page 51 and 52:
5:45 PM 699. Defining Latent and/or
Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
Page 59 and 60:
• discuss the principles of early
Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
Page 65 and 66:
ACR Plenary Session II: Discovery 2
Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
Page 69 and 70:
Session Overview: As a clinical edu
Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
Page 77 and 78:
2:45 PM 1405. Development of a Visi
Page 79 and 80:
4:30 PM Anti-citrullinated Protein
Page 81 and 82:
of Experimental Orthopedics, Univer
Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
Page 91 and 92:
• compare the prevalence and epid
Page 93 and 94:
6:45 PM Macrophage Activation Syndr
Page 95 and 96:
Page 97 and 98:
Session Overview: This roundtable d
Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
Page 103 and 104:
• describe the role of IL-1 and I
Page 105 and 106:
Session Overview: For the clinician
Page 107 and 108:
• identify the aspects for day-to
Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
Page 111 and 112:
Session Overview: Ultrasound and ma
Page 113 and 114:
Session Overview: Fifty percent of
Page 115 and 116:
1:20 PM Academic Rheumatology Seth
Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
Page 123 and 124:
Session Overview: We are witnessing
Page 125 and 126:
Session Overview: Systemic sclerosi
Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
Page 131 and 132:
4:30 PM 2198. Association between V
Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
Page 137 and 138:
• apply these basic statistics to
Page 139 and 140:
9:15 AM The ACR/EULAR Definition of
Page 141 and 142:
Immunology, Oslo University Hospita
Page 143 and 144:
9:15 AM 2239. Factors Associated wi
Page 145 and 146:
Page 147 and 148:
Mikkel Østergaard 6 , Paul Emery 4
Page 149 and 150:
Ende 4 , 1 Department of Rheumatolo
Page 151 and 152:
ACR Poster Session A Cytokines, Med
Page 153 and 154:
ACR Poster Session A 51. Associatio
Page 155 and 156:
ACR Poster Session A 83. Respirator
Page 157 and 158:
ACR Poster Session A 121. Bone Dens
Page 159 and 160:
ACR Poster Session A 142. The Intra
Page 161 and 162:
ACR Poster Session A 171. Early Pro
Page 163 and 164:
ACR Poster Session A Pediatric Rheu
Page 165 and 166:
ACR Poster Session A 233. Prevalenc
Page 167 and 168: ACR Poster Session A 266. Subtype S
Page 169 and 170: ACR Poster Session A 297. Body Weig
Page 171 and 172: ACR Poster Session A 325. Patient R
Page 173 and 174: ACR Poster Session A 356. Influence
Page 175 and 176: ACR Poster Session A 383. Efficacy
Page 177 and 178: ACR Poster Session A 409. Rituximab
Page 179 and 180: ACR Poster Session A 441. Recombina
Page 181 and 182: ACR Poster Session A 465. Immunoglo
Page 183 and 184: ACR Poster Session A 496. IRF8 Alle
Page 185 and 186: ACR Poster Session A 521. DC-STAMP
Page 187 and 188: ACR Poster Session A 546. Prevalenc
Page 189 and 190: ACR Poster Session A 571. Epidemiol
Page 191 and 192: ACR Poster Session A 599. Validatio
Page 193 and 194: ACR/ARHP Poster Session B Halls B1
Page 195 and 196: ACR Poster Session B 767. Economic
Page 197 and 198: ACR/ARHP Poster Session B 792. The
Page 199 and 200: ACR/ARHP Poster Session B Universit
Page 201 and 202: ACR/ARHP Poster Session B 848. Cell
Page 203 and 204: ACR/ARHP Poster Session B 886. Scre
Page 205 and 206: ACR/ARHP Poster Session B 909. Regu
Page 207 and 208: ACR/ARHP Poster Session B 935. The
Page 209 and 210: ACR/ARHP Poster Session B 967. Frac
Page 211 and 212: ACR Poster Session B 993. Early Exp
Page 213 and 214: ACR/ARHP Poster Session B 1022. Com
Page 215 and 216: ACR/ARHP Poster Session B 1055. Son
Page 217: ACR Poster Session B 1084. Gene Exp
Page 221 and 222: ACR Poster Session B hiroshima Memo
Page 223 and 224: ACR/ARHP Poster Session B 1166. Pre
Page 225 and 226: ACR/ARHP Poster Session B 1199. Typ
Page 227 and 228: ACR/ARHP Poster Session B 1225. Phy
Page 229 and 230: ACR/ARHP Poster Session B 1262. Lat
Page 231 and 232: ACR/ARHP Poster Session B 1294. End
Page 233 and 234: ACR/ARHP Poster Session B 1321. Cha
Page 235 and 236: ACR/ARHP Poster Session C Halls B1
Page 237 and 238: ACR/ARHP Poster Session C 1495. S10
Page 239 and 240: ACR/ARHP Poster Session C 1524. Inc
Page 241 and 242: ACR/ARHP Poster Session C 1555. Pro
Page 243 and 244: ACR/ARHP Poster Session C 1583. Ass
Page 245 and 246: ACR/ARHP Poster Session C 1596. Gen
Page 247 and 248: ACR/ARHP Poster Session C 1622. Flu
Page 249 and 250: ACR/ARHP Poster Session C Miscellan
Page 251 and 252: ACR/ARHP Poster Session C L. Woodwa
Page 253 and 254: ACR/ARHP Poster Session C 1692. Res
Page 255 and 256: ACR/ARHP Poster Session C 1719. Los
Page 257 and 258: ACR/ARHP Poster Session C 1749. Con
Page 259 and 260: ACR/ARHP Poster Session C 1780. Tow
Page 261 and 262: ACR/ARHP Poster Session C 1804. Eff
Page 263 and 264: ACR/ARHP Poster Session C Immunolog
Page 265 and 266: ACR/ARHP Poster Session C 2 Departm
Page 267 and 268: ACR/ARHP Poster Session C CA, 29 Un
Page 269 and 270:
ACR/ARHP Poster Session C 1900. IL-
Page 271 and 272:
ACR/ARHP Poster Session C 1930. Cor
Page 273 and 274:
ACR/ARHP Poster Session C 1958. The
Page 275 and 276:
ACR/ARHP Poster Session C 1988. Cha
Page 277 and 278:
ACR/ARHP Poster Session C 2015. CpG
Page 279 and 280:
ACR/ARHP Poster Session C 2038. Pri
Page 281 and 282:
ACR/ARHP Poster Session C 2070. Ass
Page 283 and 284:
REF Industry Roundtable-supported S
Page 285 and 286:
REF Industry Roundtable-supported S
Page 287 and 288:
INDUSTRY-SUPPORTED POST-CONFERENCE
Page 289 and 290:
2010 ACR/ARHP Annual Meeting Leader
Page 291 and 292:
2010 ACR/ARHP Annual Meeting Leader
Page 293 and 294:
FLOOR PLANS 2010 Program Book 291
Page 295 and 296:
VISIT THE EXHIBIT HALL New and inno
Page 297 and 298:
EXHIBITORS La Lettre Du Rhumatologu
Page 299 and 300:
ACKNOWLEDGEMENTS The ACR, the ARHP
Page 301 and 302:
ACR/ARHP/REF STAFF LISTING Administ
Page 303 and 304:
A Ahmed, Rafi, PhD T cell Memory .
Page 305 and 306:
Cooper, Max D, MD Introduction . .
Page 307 and 308:
Gerlag, Danielle Marie, MD, PhD The
Page 309 and 310:
Physical Examination Skills for Imp
Page 311 and 312:
Meroni, Pierluigi, MD Autoantibodie
Page 313 and 314:
Rogers, Joan C, PhD, OTR/ L Underst
Page 315 and 316:
Terkeltaub, Robert, MD Crystallizin
Page 317 and 318:
A Aarden, L 1825 Aarrass, S 1519, 1
Page 319 and 320:
Bakker, AAB 1095 Barendregt, B 753
Page 321 and 322:
Boutin-Le Thi Huong, D 478 Bout-Tab
Page 323 and 324:
Chatham, WW 457, 1146, 1454, 1457,
Page 325 and 326:
Daudon, M 875 Daugas, E 2009 Davatc
Page 327 and 328:
Ehst, B 758 Eicher, JL 688 Eisen, S
Page 329 and 330:
Gabay, OH 1484 Gaber, T 630, 1418 G
Page 331 and 332:
Guan, M 965 Guañabens, N 975 Gudbj
Page 333 and 334:
Homme, CL 730 Honda, E 434 Hong, JY
Page 335 and 336:
Kambayashi, T 1354 Kamdar, AA 1160
Page 337 and 338:
Kuller, LH 71 Kumabe, M 1164 Kumaga
Page 339 and 340:
Looney, C 941 Looney, MR 609 Looney
Page 341 and 342:
McCarthy, GM 1109, 1306, 1426 McCau
Page 343 and 344:
Myouzen, K 1577 Mysiw, WJ 2096 Mysl
Page 345 and 346:
Pans, M 1834 Parra, ER 605, 887 Ped
Page 347 and 348:
Radka, S 1174 Radner, H 296, 1745 R
Page 349 and 350:
Sack, KE 1898 Sacli, SF 1312 Saddic
Page 351 and 352:
1463, 2071, 2140, 2141 Singh, K 212
Page 353 and 354:
Takahata, M 1492 Takasaki, Y 1731 T
Page 355 and 356:
636 van Dongen, CJJ 90 Van Doornum,
Page 357 and 358:
Witte, T 824, 1578, 1579, 2214 Witt
Page 359 and 360:
A α-galactosylceramide 505 A2A kno
Page 361 and 362:
Behcet’s syndrome 1284, 1288, 129
Page 363 and 364:
cost-utility 759, 1539 couples 1324
Page 365 and 366:
fibroblast like synoviocyte 27 fibr
Page 367 and 368:
impact 1063, 1325 inactive disease
Page 369 and 370:
methylation 826, 1253, 1489 methylt
Page 371 and 372:
233, 234, 240, 243, 252, 262, 268,
Page 373 and 374:
1599, 1600, 1603, 1605, 1606, 1609,
Page 375 and 376:
1226, 1227, 1229, 1230, 1231, 1233,
Page 377 and 378:
Abelson, Abby Goulder, MD Education
Page 379 and 380:
Massarotti, Elena M, MD Systemic Lu
Page 381 and 382:
ACR Annual Meeting fellowS-in-train
Page 383 and 384:
NOTES 2010 Program Book 381
Page 385 and 386:
Enbrel ® (etanercept) Brief Summar
Page 387 and 388:
Prescription Enbrel ® (etanercept)
show all

B O O K - American College of Rheumatology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?